Regulus Therapeutics Inc (NASDAQ:RGLS) – Investment analysts at Wedbush cut their FY2017 earnings per share estimates for shares of Regulus Therapeutics in a research note issued on Monday. Wedbush analyst L. Moussatos now expects that the biopharmaceutical company will earn ($0.95) per share for the year, down from their prior estimate of ($0.88). Wedbush currently has a “Outperform” rating and a $4.00 target price on the stock. Wedbush also issued estimates for Regulus Therapeutics’ Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at ($0.11) EPS, FY2018 earnings at ($0.46) EPS, FY2019 earnings at ($0.48) EPS, FY2020 earnings at ($0.56) EPS and FY2021 earnings at ($0.21) EPS.

Several other equities research analysts have also commented on RGLS. Zacks Investment Research lowered Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $2.60.

Shares of Regulus Therapeutics (RGLS) opened at $0.90 on Wednesday. Regulus Therapeutics has a 52-week low of $0.79 and a 52-week high of $2.75. The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41.

A number of large investors have recently made changes to their positions in RGLS. NEA Management Company LLC bought a new position in Regulus Therapeutics in the third quarter worth approximately $13,737,000. EcoR1 Capital LLC boosted its holdings in Regulus Therapeutics by 145.6% in the second quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock worth $3,656,000 after acquiring an additional 2,199,144 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new position in Regulus Therapeutics in the third quarter worth approximately $750,000. South Dakota Investment Council boosted its holdings in Regulus Therapeutics by 37.1% in the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after acquiring an additional 492,969 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new position in Regulus Therapeutics in the third quarter worth approximately $347,000. Institutional investors and hedge funds own 59.41% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “FY2017 Earnings Forecast for Regulus Therapeutics Inc (RGLS) Issued By Wedbush” was posted by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/12/15/fy2017-earnings-forecast-for-regulus-therapeutics-inc-rgls-issued-by-wedbush.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.